EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influence of the Nanocarrier Type

Julia Sapienza Passos, Giovanna B de Melo, Giovanna C Salata iD, João Agostinho Machado-Neto iD, Alyssa Panitch iD, Luciana B Lopes iD

Molecular Pharmaceutics · 2026

DOI: 10.1021/acs.molpharmaceut.5c01740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Julia Sapienza Passos und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Sao Paulo 05508-000, Brazil. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Paclitaxel, Nanoparticle Drug Delivery System, Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico, Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo, Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanostructured lipid carriers (NLCs) and lipid-polymeric hybrid nanoparticles (H-NPs) were developed for the local administration of paclitaxel (PTX) and breast cancer therapy. Here, we investigated how nanoparticle type and composition influence the molecular effects and in vivo antiangiogenic activity of PTX. Elevated BAX expression and PARP-1 cleavage in MCF-7 and MDA-MB-231 breast cancer cells treated with nanoencapsulated PTX indicate that apoptosis is the primary mechanism of cell death, regardless of the nanocarrier type. However, distinct molecular effects were observed for other markers. Both unloaded nanocarriers increased α-tubulin acetylation in MCF-7 cells, indicating an intrinsic ability of the carriers to modulate cytoskeletal organization. Upon PTX loading, these effects became carrier-dependent: NLC-PTX induced higher α-tubulin acetylation than H-NP-PTX compared to the PTX solution. Moreover, in MCF-7 cells, NLC-PTX, but not H-NP-PTX, markedly enhanced drug-induced DNA damage, increasing γH2AX expression by 13.4-fold compared to PTX as a solution. These findings suggest that the nanocarriers not only act as delivery systems but may also confer additional biological effects that may contribute to PTX cytotoxicity. In the chicken chorioallantoic membrane model, nanoencapsulation reduced PTX-induced irritation from moderately irritant (irritation score 6) to nonirritant while preserving its antiangiogenic activity, achieving a 6.1-7.8-fold inhibition of vessel growth at subcytotoxic doses. Collectively, these results highlight nanoencapsulation as a promising strategy to potentiate PTX activity while improving safety for local breast cancer therapy. The distinct molecular responses of lipid and hybrid systems demonstrate that nanocarrier composition and structure modulate biological outcomes, underscoring the importance of rational nanocarrier design to overcome current therapeutic challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsPaclitaxelNanoparticle Drug Delivery SystemBreast NeoplasmsNeovascularization, PathologicLipidsHumansFemaleChick EmbryoAnimalsMCF-7 CellsMDA-MB-231 CellsApoptosisDNA DamageAngiogenesis

Stichwörter der Autor:innen

breast cancerhybrid nanoparticlesnanostructured lipid carrierspaclitaxelpharmacodynamics

Substanzen

Angiogenesis InhibitorsPaclitaxelNanoparticle Drug Delivery SystemLipids

Autor:innen und Institutionen

  • Department of Pharmacology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Sao Paulo 05508-000, Brazil.
  • Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, United States.

ORCID-Profile: Giovanna C Salata, João Agostinho Machado-Neto, Alyssa Panitch, Luciana B Lopes

Förderung

  • Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico
  • Funda??o de Amparo ? Pesquisa do Estado de S?o Paulo
  • Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior

Zitieren

APA

Passos, J. S., de Melo, G. B., Salata, G. C., Machado-Neto, J. A., Panitch, A., & Lopes, L. B. (2026). Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influence of the Nanocarrier Type. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c01740

Vancouver

Passos JS, de Melo GB, Salata GC, Machado-Neto JA, Panitch A, Lopes LB. Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influence of the Nanocarrier Type. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.5c01740

BibTeX
@article{Passos2026,
  author = {Passos, Julia Sapienza and de Melo, Giovanna B and Salata, Giovanna C and Machado-Neto, João Agostinho and Panitch, Alyssa and Lopes, Luciana B},
  title = {Molecular and Antiangiogenic Effects of Paclitaxel-Loaded Nanoparticles: Influence of the Nanocarrier Type},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  doi = {10.1021/acs.molpharmaceut.5c01740}
}
Kostenlos starten →